Back to search
FDAFDA · Food and drugs·Recall number D-0621-2020

EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,

Published December 11, 2019 · Recall initiated: November 21, 2019

Summary

FDA records drug Class II recall D-0621-2020, published December 11, 2019 and initiated November 21, 2019. Recalling firm: Pacira Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 910 20 mL vials; Lot: Pacira Lot #: 19-5002, Patheon manufacturer Lot #: 098214; Exp. Date: Dec 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Sub Potent Drug: Out of Specification (OOS)

What to do

Voluntary: Firm initiated · Letter

Get an email if EXPAREL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
EXPAREL
Manufacturer
Pacira Pharmaceuticals, Inc.
Distributor
Distributed Nationwide in the USA
Lot
Pacira Lot #: 19-5002, Patheon manufacturer Lot #: 098214; Exp. Date: Dec 2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20, recalled?

Yes. FDA published recall D-0621-2020 on December 11, 2019. Reported hazard: Sub Potent Drug: Out of Specification (OOS)

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: EXPAREL.